Physician profile
Kelli Spurlock
NPI 1124651393
$504.05
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $12.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $205.49 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $66.68 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $54.32 | 2021 | |
| Avanir Pharmaceuticals, INC. | $44.75 | 2021 | |
| Lilly USA, LLC | $35.87 | 2021 | |
| Novo Nordisk INC | $35.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.09 | 2021 | |
| Smith+Nephew, INC. | $11.21 | 2021 | |
| Redhill Biopharma INC. | $11.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Spurlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.